Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.22.2
Revenues from Contracts and Significant Customers (Tables)
6 Months Ended
Jun. 30, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended June 30, 

​

Six Months Ended June 30, 

​

    

2022

    

2021

    

2022

    

2021

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

Qbrexza®

​

$

6,111

​

$

4,568

​

$

13,487

​

​

4,568

Accutane®

​

​

5,200

​

​

1,945

​

​

10,107

​

​

2,141

Amzeeq®

​

​

1,265

​

​

—

​

​

4,731

​

​

—

Targadox®

​

​

2,756

​

​

5,727

​

​

5,390

​

$

12,926

Ximino®

​

​

1,035

​

​

1,312

​

​

2,002

​

​

3,413

Zilxi®

​

​

555

​

​

—

​

​

1,297

​

​

—

Exelderm®

​

​

1,313

​

​

1,736

​

​

2,017

​

​

2,953

Other branded revenue

​

​

—

​

​

—

​

​

—

​

​

6

Collaboration revenue

​

​

577

​

​

2,400

​

​

1,154

​

​

3,200

Revenue – related party

​

 

18

​

 

155

​

 

70

​

 

223

Other revenue

​

​

56

​

​

—

​

​

2,556

​

 

—

Net revenue

​

$

18,886

​

$

17,843

​

$

42,811

​

$

29,430